SETD2 inactivating mutations are frequently found in multiple types of cancer, including ccRCC (Dalgliesh et al., 2010; Duns et al., 2010; Gerlinger et al., 2012; Sato et al., 2013; Bihr et al., 2019), high-grade gliomas (Fontebasso et al., 2013) and leukemias (Zhang et al., 2012; Zhu et al., 2014; Mar et al., 2014). Here, SETD2 is linked to nonpapillary renal cell carcinoma.